Response Evaluation Criteria in Cancer of the Liver (RECICL 2019 revised version)

[1]  Y. Imai,et al.  Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. , 2018, The lancet. Gastroenterology & hepatology.

[2]  T. Meyer,et al.  mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[3]  M. Kudo,et al.  Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. , 2017, Journal of hepatology.

[4]  T. Murakami,et al.  Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version) , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[5]  A. Russo,et al.  Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis , 2015, PloS one.

[6]  M. Kudo,et al.  Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma , 2014, Journal of Gastroenterology.

[7]  M. Makuuchi,et al.  Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version) , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[9]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[10]  M. Yoshikawa,et al.  Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. , 2000, AJR. American journal of roentgenology.

[11]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[12]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.